A Case Report of Excessive Inflammation After TACE That Mimicked Tumor Invasion of Adjacent Tissues.

Abstract

Liver transplantation is the most reliable treatment strategy for hepatocellular carcinoma (HCC) within certain selected criteria. Patients with HCC may not have access to liver donation at the appropriate time and this may result in fall out from the transplant list. To avoid this, bridging therapy has been recommended for patients with HCC to prevent progression of the tumor and to ensure that patients remain within the criteria of transplantation when the organ finally becomes available. Transcatheter arterial chemoembolization (TACE) is a commonly used bridging therapy in patients with HCC awaiting transplantation.